Abstract: When discovered, anti-tuberculosis drugs were always administered in Daily-doses; it worked wonders! Later, studies claimed these drugs could cure even in thrice-weekly doses (intermittently). Not everyone believed that. Three Reviews (Cochrane, Thorax, Azhar) appear unconvinced! Also, most nations (including 20 High TB Burden Countries) practice time-tested Daily dosing! INDIA adopted a unique low-cost, thrice-weekly regimen around 2000. During 15 years, under national program, Thrice-weekly doses have been administered to 15 million TB patients, self-claiming 85% success. To revisit long-term outcome of all registered patients in a district; identify the one, who didn't achieve long-lasting recovery with a single course, was later found re-registered for a second innings; his name figures twice in national registry (a Repeater). Author heads District Tuberculosis Center, Faridabad, India; monitors thousands of current/ex-patients on Thrice-weekly regimen. By providence, he enjoys unique access to registered patients, data, district TB-workers. Two methods of data collection: 1. Author motivated district work-force; jointly conducted systematic Retrospective Record Review of hand-written registers of past 15 years, one at a time-thus identified over 1,575 Repeaters. 2. Author has been conducting ongoing Clinical Audit in his busy TB OPD for 6 years. He is able to cherry-pick (average) one Repeater per day; thus tracked 3,100 Repeaters-about half come in from Delhi's premier TB institutes, duly diagnosed, referred in for local registration for Re-treatment. Long-term fate of 36,785 registered TB patients could be analyzed. 4,675 patients observed to have returned sick, meriting Re-registration, Re-treatment; thus over 12.7 % registered twice/thrice (names, unique govt. ID's, irrefutable evidence enclosed)-an adverse outcome, unreported thus far-a bubble. Besides, study recorded 1,590 (5%) Deaths; 2,590 (8%) Defaulters. Under India's routine program conditions, Thrice-weekly regimen is ineffective. Too many (12.7%) patients come back sick, which may promote drug-resistance on industrial scale! A global threat!
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Introduction
Some 95% of cases and 98% of (global) TB (tuberculosis) deaths occur in poor countries [1] . India has the highest burden of tuberculosis in the world with over two million incident cases amounting to more than fifth of global burden [2] . Thus, India generates about 12,602 TB patients within two days while US reported only 10,528 cases in a full year in 2011 [3] . Two Indians die of TB every three minutes! Real TB battle ensues (not in the affluent West) but in 22 High TB Burden Countries (HBC's)-like India, China, South Africa, Indonesia, Bangladesh, Pakistan etc.
Discovery of five primary anti-TB drugs (1944-1966) was a miracle for mankind. Those days, these medicines were always administered on a Daily-dose basis. And which worked wonders; TB declined in several Western nations; thus, history itself validates Daily-dosing, which requires no further evidence. Why re-invent the wheel?
Decades later, some studies claimed that anti-TB medicines were equally effective even when administered intermittently-say as Thrice-weekly doses (instead of Daily). However, most scientists were not convinced. 20 (out of 22) High TB Burden Countries continue to practice Daily-dosing schedule [4] . Probably, choosing to exercise caution, they preferred to stick to the traditional, time-tested Daily-dosing.
India
However, India is one of the few exceptions. She switched over to a unique, low cost, Thrice-weekly regimen on a massive scale. Since 1998, Revised National TB Control Program (RNTCP) of India has placed on treatment more than 14.2 million TB patients [2] -all administered three doses per week.
Please remember, if any more evidence is needed, it is for efficacy of Thrice-weekly dose and not for Daily regimen (as stated above).
A Systematic Review in British Medical Journal [5] concluded that despite millions treated in 10 years, few studies examined whether DOTS (directly observed treatment, short course) provides lasting cure or not-just what this present study undertakes.
Objective
To evaluate efficacy of India's TB program under routine program conditions. To quantify Re-registration (Relapse and recurrence etc.), which is a reliable indicator of efficacy.
Aim is to find a registered patient who (at a later date) returned sick and got re-registered again.
Long term outcome of all patients registered during 'thrice-weekly era' was revisited in district Faridabad so as to identify such patients who undertook two cycles of thrice-weekly DOTS. In other words, the study computes re-registration-an unfavorable outcome of treatment.
Why This Study Took 6 Years?
This unintended operational analysis got triggered in 2010 by curiosity and craving for truth, not academics; gathered momentum despite initial doubts, chaos, and confusion; aimed perfection not time-frames or traditional research-frameworks. IN INDIA, RECORDS OF TB PATIENTS ARE HAND-WRITTEN, not computerized or digitized. To search a patient's name in a bulky manual register or to trace him in a thickly populated slum is like finding a needle in a hay-stack. You are literally at the mercy of 'that' local NTP (National TB Program) worker-who had then performed home-visits, given him doses personally and had scribbled those original entries; no easy shortcuts. 'Harmonious alliance forged between workers of NTP' is the soul of this labor-intensive and time-consuming exercise. Results are therefore reasonably credible, accurate and verifiable.
Subjects and Methods

Search Strategy
To find a TB patient found registered twice (or more often) under 'Thrice-weekly' DOTS program. Re-treatment patients emerging out of purely private sector pipeline were also identified but were of no interest and were painstakingly excluded/discarded from this study, because private doctors in India (ironically) use daily dose regimen.
Also, all deaths, and defaulters (who failed to complete medication) were enlisted, quantified and digitized.
Two Methods of Data Collection (Overlapping)
Retrospective Record Review
Author was intrigued to notice trickle of 'ex-patients, sick again' (Repeaters) in OPD. So had been field workers; their frustration served as bonding spirit. Possessed with a unanimous desire to somehow stem the rot, the team formed an informal alliance. They would go out of their way to answer author's never-ending 24X7 queries. More and more NTP workers, by providence, began voluntarily digging up Repeaters, families, homes falling within their territory and unearthed old dust-laden entries that no one else could have ever retrieved. Author kept inspiring and exhorting them relentlessly-in OPD, monthly-meetings, training-sessions, and (some key ones) on phone. Author cajoled their memory, "did you ever give anyone DOTS twice?" which means 14-month stint with a difficult patient-often hard-to-forget. Names emerged. As mutual trust grew, synchronization and learning curve improved, workers began fetching past registers for joint scrutiny.
Merely procuring a hand-written register without its original author is not much use; it is like a guitar without the guitarist; one invariably got lost in jungle of data. Without willful co-operation of original writer, hand-written DOTS data is impenetrable; no shortcuts possible, hence time-consuming (6 years).
During initial 3 years (2010 through 2012), author systematically perused most district registers (of distant past) kept at TB-Units, PHIs, sub-centers, sputum Labs, one by one-to cherry pick Repeaters, and failures (who indeed require Re-treatment), deaths and defaulters recorded therein. Books were promptly returned, often within a day, as manual entry is a dynamic 24X7 process.
In all, 1,575 Repeaters could be identified from registers of distant past (about twelve) years.
Clinical Audit and Collection of Current Data
At district govt. hospital, in busy, exclusive TB OPD, 6 days a week, author personally conducts clinical audit. He interrogates each TB patient arriving for-diagnosis, follow-up, or diagnosed elsewhere but referred-in for local registration for Re-treatment. His favorite question is "did you ever take Thrice-weekly DOTS from govt. in the past?" If yes, this current TB episode (if now confirmed) is the second innings, making him a Repeater-a suitable candidate for this study. Once so established, author would then record in his diary and laptop all details and retain complete documentary evidence-patient's name, father's/husband's name, address, Lab. No. of sputum-positive report, mobile no.; photos were clicked of patient himself, X-ray (sometimes), previous TB ID card, refer form, discharge slip, relevant FNAC/biopsy reports etc.
Unverified cases were excluded. During 6 years of intensive clinical audit, author could identify about 3,100 Repeaters (average one repeater detected per day) in OPD.
AUTHOR'S ROLE in these 3,100 cases (Repeaters) was twofold:
Confirmation of first innings: To verify the basic precondition-that the patient had indeed taken 'thrice-weekly DOTS' in the past, through skillful history-taking: [Then, medication was free of cost, from a govt. outlet (and not a private doctor), medicine-box delivered somewhere in the neighborhood, health-worker watched him swallow 7 tablets, all at once, on alternate days (thrice-weekly), reclaiming empty blister packs and insisted on repetitive sputum tests etc. Wherever available, author perused, filmed, collected old records (cards etc.). It was ensured that the previous episode was not prior to 2000 (pre-DOTS era)].
Confirmation of second innings: To confirm that now patient has active TB disease at present. In this, help came from numerous quarters:
Half of such Repeaters (about 1,500) arrived 'already-diagnosed', ripe and ready to be plucked-from credible sources: (i)
Simultaneously, author would trigger the process to track down patient's previous TB No. from past registers, through consistent 24X7 interactions with relevant field-workers (by method no.1 above).
Some Repeaters' were diagnosed and referred by our own in-house physicians, surgeons, pediatricians, and orthopedicians etc. in district hospital, which has over 40 doctors. They have already clinched the current diagnosis of active TB (2nd innings, necessitating re-treatment now).
Some Repeaters came straight to author's OPD, where he would confirm that they were indeed sick again and warranted re-treatment; a vast majority being sputum-positive; laboratory no. duly recorded. Some repeaters were also sputum negative PTB. Some were Extra-PTB cases-often FNAC positive or having duly consulted a relevant specialist. Author exercised due restraint while labeling patients.
Also, district's peripheral army of 'trained' doctors (stationed at 9 TB Units, PHCs etc. as detailed under 'extrapolation') keeps enrolling Repeaters routinely, dispatching them straight to respective destination DOT centers; author nowhere in the picture. Weeks/months later, some loyal workers would possibly inform the author (method no.1 above).
Like a command-center, author kept multi-tasking-demanding, receiving, applauding, digitizing and indexing incoming information-drop by drop, so as to complete the big picture, to make sense of it all. 
Conclusions
Under routine program conditions, India's unique fully-intermittent, Thrice-weekly regimen of anti-tuberculosis drugs has not proven effective; it fails to provide reliable, lasting cure/relief. At least 12.7% of registered patients come back-sick again, meriting Re-treatment, which might be promoting multi-drug resistance on an industrial scale, a global threat.
India ought to revert back to the time-tested daily regimen, before it is too late.
Besides, study found 4.9% Deaths, 8% Default. More fool-proof mechanism for independent data-verification and automatic course-correction, like systematic clinical audits, must be built into the original design of a public health program, run by a single agency; or else, a bubble may form. This study is nothing but incarnation of that (invisible) bubble within RNTCP, run solely by Govt. of India.
Evidence in Literature
To resolve the 'Daily versus Thrice-weekly' controversy, three Systematic Reviews are available. Cochrane [6] found 'insufficient evidence to compare…' the two Review in Thorax [7] '…justifies…Daily… (particularly in initial phase) …' India specific review by Azhar [8] stated 'Relapse rate is high (almost 10%) in India….higher than…international studies.' He speculates that '….. Daily regimen might have lower relapse rates compared to an intermittent regimen'. Furthermore, In South India, of 503 patients cured, 9.5% relapsed within 6 months [9] . Out of 657 successfully treated NSP TB patients, 10.85% relapsed and another 5.9% died due to TB within 2 years [10] . Out of 4,905 successfully treated Cat I patients, 442 (9%) presented as relapses [11] . Daily anti-tuberculosis treatment is more effective than thrice weekly treatment for the treatment of tubercular (TB) meningitis [12] . Twice-weekly intermittent SCT is less likely to cure TB in children [13] . In HIV positive, Daily regimen or at least Daily in IP, followed by thrice weekly CP is better [14] . Cavitary tuberculosis is best treated with …Daily IP… [15] .
[Indian program is sputum-smear based; chest X-ray not mandatory; which patient has cavities is unknown. Follow up of even sputum-negative PTB (diagnosed by X-rays) is by sputum-tests alone]!
Discussion
(1) To cure TB, first opportunity is ideal; thereafter, medicines become less effective, results inferior. Favorable outcomes were significantly less in the retreatment group (66.47%) as compared to new smear positive cases (84.28%) [16] . This is possibly due to generation of some degree of drug-resistance.
(2) Each repeat episode is a baby step towards development of drug-resistance. Of 15 million Indians registered so far, 12.7% took two cycles; about 2 million repeat episodes, which amounts to promotion of drug-resistance at an industrial scale; potential threat for the entire world.
(3) DOTS is misnomer-a confusing term. Several national TB programs, even poles apart, are all popularly called DOTS.
Nepal's DOTS is daily-regimen, Indian DOTS is thrice-weekly. To a retreatment case, both countries offer Injection Streptomycin for initial two months; that comes to 60 injections (one vial daily) in Nepal; 24 injections (three per week for 8 weeks) in India, which appears desperately inadequate, especially in Failure cases, who respond more poorly than relapse cases. The 'Failure' cases of Category I subsequently treated with Category II were observed to have significantly lower success rates (P = 0.05) as compared to Relapse cases [11] . The need for re-appraisal of Category II re-treatment regimen for 'Failure' cases among Cat I is suggested [11] . Karma also hinted that Category I failures are more likely to fail Category II (re-treatment) [17] . (4) Under RNTCP, cured patients are not followed up to see if they shall relapse, hence no systematic, precise quantification of relapse! (5) Betraying total lack of conviction in her own thrice-weekly system, India has recently reverted back to Daily-regimen in dealing with her drug-resistant cases.
(6) WHO frames its future guidelines based upon 'published research', which is scanty. The exercise essentially ignores a mammoth resource-NTP data generated worldwide.
(7) Randomised Controlled Trial versus Audit in Poor Countries:
RCT is needed to prove more Relapse in thrice-weekly than in Daily. Because if proven right, a simple change to Daily dose would be life-saving.
But, RCT requires funds, manpower but first, a high level decision.
RCT for Relapse is likely to take at least 10 years. Because, after initial treatment of a year, one has to wait for 5-7 years to see how many of them relapse.
With MDR breathing down our neck, we don't have 10 years.
Time to do RCT was: 1990s when India was funded big time to adopt thrice-weekly on insufficient evidence.
Or in 2005 when a South Indian study found 12% Relapse.
Or in 2008 when a large Delhi study found 9% Relapse.
Grave Ommissions. Typically, no accountability. At present, Retrospective is the way to go. And, outcome of 15 million patients lies buried in Indian Registers; please digitize and share.
No doubt, Audit is a low grade evidence, with risk of bias and fraud. But, here is a clinching, whistle-blower, audit of 35,000 patients-very large, credible and verifiable-as good as RCT.
Constraints
(1) HAND-WRITTEN AND NON-DIGITIZED: India is an ideal laboratory to resolve the 'daily versus thrice-weekly' controversy. Details of 15 million patients fed thrice-weekly doses stand recorded within India's hand-written registers. Their custodian (govt. of India) and technical advisers (WHO) did not timely digitize, share, release, publish or capture this invisible goldmine of retrospective wisdom, which still remains out of reach of potential researchers. What a paradox! The entire world gropes for answers. India began to digitize in late 2012 through case-based Nikshay software, which is still in its infancy, struggling yet to update even the current data.
(2) To search a name in a thick hand-written register is like finding a needle in a hay-stack, more so, retrospectively. Or if patient took DOTS from another TB Unit, district, city or state. Manual entries suffer from bad illegible writing, wrong names/address/spellings, no phone number, faded ink, over-writing, cutting; missing, torn or moth-eaten pages.
(3) OPAQUE: RNTCP is designed to thwart transparency. In each of 2,698 sub-district TB Units of India, a single contractual supervisor (STS) monopolizes over gathering field-data, compiling reports (unsupervised) and e-mailing them (unverified/countersigned blindly) into public domain! Floods or earthquake, STS must achieve pre-set targets! Or else, he is fired; his children starve; fudging and then safeguarding data becomes a survival-skill. Hence it is no transparency, virtual impenetrability. Inspectors converging from outside (for helicopter surveys), can hardly uncover truth; hence, bubble-formation over time.
(4) NO SYSTEMATIC CATALOGING: 50% TB patients approach private practitioners and receive Daily-dosing, the rest receive govt.'s Thrice-weekly dose; both regimens operate side by side in India. But when a retreatment case presents himself for registration under DOTS, program doesn't ask "Source of previous anti-TB treatment: DOTS or Private sector?" Appropriate cataloging (so easy at entry-point) is not done; he enters untagged; RNTCP data-bank churns up both types, escalating confusion. Hence, the long time taken by this study.
(5) LOW PROFILE: Author worked in silence, quizzed clueless but motivated workers on a mission-to-know basis, in return divulging little. India has no legal protection for whistle-blowers. Govt. is a powerful giant; capable of squashing critics; retribution is quick, efficient. DOTS workers (including author) are on yearly-contract, vulnerable. Once jobs are at stake, entire system may turn hostile, denying data or even resorting to resurrecting brand new fake district registers overnight! For this reason, no names are in acknowledgement section. Govt. doctors are mortally afraid to (openly) criticize govt. policy; they are brain-washed that 'DOTS thrives in over hundred countries', unaware that it is mostly Daily DOTS. Besides, it is backed by WHO, which is considered above suspicion; no one even begins to question.
Easily verifiable, transparent excel-data with names and unique ID's of about 9,600 patients with clinching evidence is attached. Furthermore, voluminous manual backup, software data containing phone no. of patients, workers, and sputum Lab No.'s, and heavy 16-GB photo-albums (withheld) but remain available with author.
Govt. of India didn't systematically conduct or encourage any studies over thrice-weekly program. Hence, these remain meager, published locally, circulated poorly, quoted rarely; hence ineffective. Besides, thrice-weekly topic doesn't directly concern the rest of the world (which largely uses Daily dose). For international journals, subject is low priority, unexciting.
(10) EXTRAPOLATION: This is purely a study of Indian DOTS. Results are India-specific. They can't be automatically extrapolated over DOTS of other nations (having daily regimen and different field conditions). However, findings ought to be extrapolated over India's all 662 districts because same model (as per RNTCP guidelines) operates all over! Faridabad represents 'routine program conditions' prevailing across India.
To dismiss it as exception would be a dishonest denial. The district offers a large sample; it registers over 3,000 TB cases annually (France does 2,700). Situated near Delhi, monitored intensively, having ten TBHV's, getting bonus help from infrastructures of ESI, RCH schemes, it consistently 'achieves' 85% success. Study reflects years of collective performance of (not just a handful of non-performing individuals but) RNTCP's routine army-25 PHIs and doctors therein; 10 TBHVs; 19 DMCs, 22 LTs; 300 DOT providers (including ANM, ASHA, AWW, GP's); 3 TB Units (one headed by the author since 6 years), 3 STSs, 3 STLSs; DTO, STO and one WHO Consultant. (As technical advisor to Govt. of India, WHO has perpetually fathered the entire process of conception, birth, expansion, and monitoring of Indian DOTS. Currently, 87 WHO Consultants serve as watchdog). an undeclared disaster; fewer than 30% patients completing year-long antique STH regimen. Belatedly, DOTS ushered in a ray of hope-generational switch to modern, short course chemotherapy. Alas, this too got contaminated with 'thrice-weekly dosing'! Another crime against humanity! No accountability ever for governments or their unions! India's euphoria over self-generated printed papers guarantees little respite in near future. Tuberculosis is blamed to play havoc with poor millions in the third world. Study uncovers the real culprit-gross policy-mismanagement. It reiterates how while seemingly championing governance, equality, justice, human rights and charity, man acts as scavenger on its own race.
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